In clinical trials, minimum clinically important difference (MCID) has attracted increasing interest as an important supportive clinical and statistical inference tool. Many estimation methods have been developed based on various intuitions, while little theoretical justification has been established. This paper proposes a new estimation framework of MCID using both diagnostic measurements and patient-reported outcomes (PRO's). The framework first formulates population-based MCID as a large margin classification problem, and then extends to personalized MCID to allow individualized thresholding value for patients whose clinical profiles may affect their PRO responses. More importantly, the proposed estimation framework is showed to be asymptotically consistent, and a finite-sample upper bound is established for its prediction accuracy compared against the ideal MCID. The advantage of our proposed method is also demonstrated in a variety of simulated experiments as well as two phase-3 clinical trials.
Introduction
In clinical trials for drugs or medical devices, statistical significance is widely used to infer the treatment effect. However, there has been growing recognition that statistical significance could be misleading when evaluating treatment effect (Jacobson et al., 1984; Jacobson and Truax, 1991) .
First, in many trials, the statistical significance of the treatment effect may have little to do with its clinical significance. It is known that statistical significance only infers the existence of treatment effect, regardless of the effect size. Further, the statistical significance could result from a small sample variability or a huge sample size, and thus provides little information about the clinical meaningfulness of the treatment (Jacobson and Truax, 1991) . Second, the statistical significance for the treatment group compared to the placebo group ignores the possible heterogeneity among individuals. For instance, in a pain reduction study, a statistically significant reduction is concluded for a test treatment while many individual patients in the treatment group actually report little improvement regarding the pain reduction (Younger et al., 2009 ).
Clinical significance is desired in practice as it provides a better assessment of the clinically meaningful improvement. It is often based on the patients' reports in a community according to certain external standards (Jacobson and Truax, 1991) . One common approach is to collect patient-reported outcomes (PRO's; FDA, 2009), such as their satisfaction of a treatment. Some earlier practice suggested to replace the statistical significance tests by analyzing the PRO's only, which is problematic due to the subjective bias in the PRO's or unreliability of a poorly designed questionnaire. Minimum clinically important difference (MCID) was discussed in Jaeschke et al. (1989) , which was intuitively defined as a thresholding value in post-treatment change, and a patient is considered experiencing a clinically meaningful improvement if her/his change exceeds the MCID. Copay et al. (2007) suggested to incorporate both certainty of effective treatment and patients' satisfactions for determining MCID.
The concept of MCID provides objective reference for clinicians and health policy makers regarding the effectiveness of the treatment, and has quickly gained its popularity among the practitioners. In 2012, U.S. Food and Drug Administration (FDA) hosted a special conference on the MCID for orthopaedic devices (http://www.fda.gov/MedicalDevices/NewEvents/ Workshops/Conferences/ucm327292.htm). Although the importance of MCID has been widely recognized, only a few ad-hoc approaches have been proposed for its estimation with little theoretical justification (Bennett, 1985; Leisenring and Alonzo, 2000; Shiu and Gatsonis, 2008) .
In this paper, the MCID is formulated as the thresholding value in post-treatment change such that the probability of disagreement between the estimated satisfaction based on the MCID and the PRO is minimized. With this framework, two scenarios are considered: population-based MCID and personalized MCID. The population-based MCID is the ideal thresholding value for the general population, and the personalized MCID allows different MCID values for individual patients based on their clinical profiles. Both scenarios can be formulated in a large margin classification framework, where the population-based MCID can be estimated via an exhaustive grid search, and the personalized MCID is modeled in a reproducing kernel Hilbert space and estimated via some non-convex optimization techniques. Most importantly, the asymptotic properties of the proposed estimation method are established for both population-based and personalized MCID's, and their fast convergence rates to the ideal performance are explicitly quantified.
The rest of the paper is organized as follows. In Section 2, a general framework for the population-based MCID is presented, and its estimation algorithm and asymptotic properties are studied. Section 3 extends the framework to the personalized MCID, and discusses the appropriate large margin loss as well as the efficient non-convex optimization technique. Section 4 establishes the asymptotic properties of our proposed method for estimating the personalized MCID. Section 5 conducts numerical experiments of our proposed method in simulated examples, and Section 6 applies our proposed method to two phase-3 clinical trial datasets. Section 7 contains some discussion, and the appendix is devoted to technical proofs.
A general framework of MCID

Formulating MCID
Suppose that a patient's diagnostic measurement X ∈ R 1 is continuously connected, and the patient-reported outcome (PRO) Y ∈ {−1, 1}, where Y = 1 denotes a clinically meaningful treatment reported by the patient and Y = −1 otherwise. Let f (x, y) and f (x) be the joint density of (X, Y ) and the marginal density of X, respectively. The MCID is formulated as the thresholding value c * such that sign(X − c * ) agrees with Y as much as possible, where sign(u) = 1 if u ≥ 0 and −1 otherwise. Mathematically, c * is defined as a solution of
where P (·) is taken with respect to both X and Y .
Lemma 1 Assume that p(x) = P (Y = 1|X = x) is continuous and increasing in x, then the ideal MCID c * satisfies
Furthermore, if p(x) is strictly increasing in x, then c * is the unique root of (2) .
Note that it is reasonable to assume that p(x) is increasing in x since patients with better diagnostic measurements are expected to be more likely to give positive responses. If p(x) is only non-decreasing, the equation in (2) may have multiple roots and a conservative choice is to set c * as the largest root. Furthermore, the continuity assumption of p(x) can be relaxed to semi-continuity, and then the equation in (2) may have no root at all. In such scenarios, it could be proved similarly as Lemma 1 that c * = argmin c {p(c) ≥ 1/2}.
It is known that the quality of the PRO's is largely affected by patients' subjectivity (Frost et al., 2007) . Such subjectivity is accounted in the proposed formulation of the MCID through p(x), which can be interpreted as the probability of patient's telling the truth. For instance, Fang (2011) considered a special case of semi-continuous p(x), and modeled the subjectivity explicitly as p(x) = Q when x ≥ c * and p(x) = 1 − Q otherwise, where Q > 1 2 measures how trustworthy the PRO's are. More importantly, the ideal MCID in (2) is less affected by the subjectivity in the PRO's, as it relies on p(x) only when x is in the neighborhood of c * . This is analogous to the Bayes rule in classification, which only relies on whether p(x) ≥ 1/2 (Lin, 2002) .
In addition, the MCID has an interesting connection with the median lethal dose in toxicology research. The median lethal dose refers to the smallest dose required to kill half of the animals that receive it after a specified test duration. To describe the interaction between dosage and mortality rate, the logistic dose-response curve is popularly used (Williams, 1986; Alho and Valtonen, 1995; Kelly, 2001) . It assumes that the mortality rate is expected to strictly increase with dose, which coincides with our assumption in Lemma 1.
Estimating MCID
The primary interest of this paper is to estimate the MCID, which is in sharp contrast to the standard classification that focuses on the classification boundary. In (2), the ideal MCID c * is defined based on p(x) that is often unavailable in practice, so the MCID needs to be estimated based on
Naturally, the expectation in (1) can be approximated by its empirical version, and the estimated MCIDĉ is defined as a solution of
Note that (3) is a simple 1-dimensional optimization problem, and the objective function remains the same for
, where x (i) is the i-th order statistic. Therefore, an exhaustive grid search scheme can be implemented, and the global minimizerĉ is simply the x i that yields the smallest objective function value. such that for sufficiently small ξ > 0, 
Weighted MCID
In many clinical studies, it is a common practice to be conservative when predicting whether the test outcome is clinically meaningful. It is then less desirable to predict positive for an unsatisfied patient than negative for a satisfied patient. To accommodate the unbalanced severity, the weighted MCID can be introduced with the weights reflecting the severity of the disagreements. Specifically, the weighted MCID c * w is defined as a solution of
where w(1) = w and w(−1) = 1 − w. Similarly as in Lemma 1, it can be shown that
where an appropriate choice of w < 1/2 leads to a conservative estimation.
The weighted MCID has another useful interpretation in the context of hypothesis testing. In particular, we denote the type-I error and type-II error as R 0 (c) = P (X − c > 0|Y = −1) and R 1 (c) = P (X − c < 0|Y = 1), respectively. Then it is natural to find c * α to solve 
Personalized MCID
In many clinical trials, it is commonly believed that patients' report could be influenced by various factors such as their expectation of treatment (Wise, 2004) . For instance, in a shoulder pain reduction study, healthy people demonstrate a higher threshold than those with chronic conditions due to their expectation of complete recovery. To allow the MCID to vary according to patients' clinical profiles, this section extends the estimation framework to personalized MCID.
Formulation
Let z denote patients' clinical profiles, and the personalized MCID c * (z) is formulated as a solution
where P is taken with respect to (X, Y, Z). Similarly as in (2), we can show that c * (z) satisfies
where
is assumed to be a continuous and strictly increasing function in x for any value of z. If only semi-continuity is assumed, the MCID can be formulated
}. It is worth pointing out that the personalized MCID in (9) differs from the Bayes rule in classification in that the candidate function in (9) has to take the form of x − c(z) in order to estimate c * (z), whereas a Bayes rule in classification searches for the optimal classification function g(x, z) that may not lead to an explicit estimation of c * (z).
The formulation in (9) is similar as in (1) with population-based c * , but the difficulty arises in the estimation part. Since the empirical version of (9) min c 1 2n
involves the 0-1 loss L 01 (u) = In this paper, we propose a novel surrogate loss, ψ δ -loss, which is defined as
The ψ δ -loss extends the ψ-loss by introducing a new parameter δ that controls the difference between the surrogate loss and the 0-1 loss. More importantly, Lemma 2 shows that the ψ δ -loss is asymptotically Fisher consistent in estimating c * (z) when δ converges to 0.
Lemma 2 For any given z, if the conditional density f z (x) is continuous and p z (x) is strictly
With the ψ δ -loss, the proposed estimation formulation for the personalized MCIDĉ(z) solves
where λ is a tuning parameter, J(c) is a penalty term, and F is set as a reproducing kernel Hilbert space (RKHS; Wahba, 1990 ). The final estimation formulation then becomes
where H K is the RKHS induced by some pre-specified kernel function K(·, ·), and J(c) =
is the associated RKHS norm of c(z). It follows from the representer theorem (Wahba, 1990 ) that the solution to (14) is of the formĉ
Non-convex optimization
Note that the cost function in (14) is non-convex, and thus we employ the difference convex algorithm (DCA; An and Tao, 1997) to tackle the non-convex optimization. The key idea of the DCA is to decompose the non-convex cost function into the difference of two convex functions, and then construct a sequence of subproblems by approximating the second convex function with its affine minorization function.
In particular, the ψ δ -loss is decomposed as
Then the cost function in (14) can be decomposed as s(w) = s 1 (w) − s 2 (w), where
and w is the coefficient vector for the RKHS representation of c(z).
Next, the DCA constructs a sequence of decreasing upper envelop of s(w) by approximating s 2 (w) with its affine minorization function,
, where w (k) is the estimated w at the k-th iteration, and ∇s 2 (w (k) ) is the subgradient of s 2 (w) at w (k) . The updated w (k+1) is then obtained by solving
The updating scheme is iterated until convergence. Although the DCA cannot guarantee global optimum, it delivers a superior numerical performance as demonstrated in the extensive simulation study in Liu et al. (2005) .
Asymptotic theory
This section quantifies the asymptotic behavior ofĉ(z) in estimating the personalized MCID. De-
) with δ n > 0, where δ and λ are rewritten as δ n and λ n to denote their dependency on n. We make the following four technical assumptions.
Assumption A. For some positive sequence s n → 0 as n → ∞, there exists c 0 (z) ∈ F, such that for sufficiently small δ n , e δn (c 0 , c
Assumption A is standard (Shen et al., 2003; Li et al., 2007) , and describes the approximation error of F in approximating c * (z).
Assumption B. There exist constants 0 < α 2 < +∞ and a 3 > 0 such that for any given z,
Assumption B is the low noise assumption that describes the distribution of the diagnostic outcome X in the neighborhood of c * (z).
Assumption C. There exist constants 0 < γ 2 < +∞ and a 4 > 0 such that for any given z,
Assumption C is implied by a Hölder continuity condition that describes the smoothness of
Before specifying Assumption D, we first define the metric entropy for any give set. For a given class B of subsets of S and any > 0,
Then the metric entropy H( , B) of B is defined as the logarithm of the cardinality of the -bracketing set of B of the smallest size. Let G(k) = {G c = {(x, z) :
Assumption D. For positive constants a 5 , a 6 and a 7 , there exists some n > 0 such that
Theorem 2 Suppose that Assumptions A-D are met. For the estimated personalized MCIDĉ(z),
there exists positive constants a 8 and a 9 such that
is bounded away from 0.
Corollary 1 Under the assumptions of Theorem
),
α 2 +1 is bounded away from 0. due to its lack of explicit estimation of c * (z).
Simulation
This section examines the proposed estimation methods for estimating MCID using simulated examples. Two scenarios are considered. Scenario I focuses on the population-based MCID for all patients, and scenario II focuses on the personalized MCID that varies among patients and relies on each patient clinical profile. To assess the estimation performance, we report the estimated MCID as well as the misclassification error (MCE) based on the testing set, which is defined as
where n test denotes the size of the testing set, andĉ(z i ) =ĉ for the population-based MCID.
Scenario I: population-based MCID
Two simulated examples are examined.
is generated as follows. First, X i is generated from U nif (−1, 1) and then Y i is generated from Bern((x i + 1)/2). Next, a sample of size n is randomly selected for training and the remaining 2000 samples are allocated for testing. is generated from Bern(F (x i )), where F (x i ) = P (X ≤ x i ). Next, a sample of size n is randomly selected for training and the remaining 2000 samples are allocated for testing.
In both examples, the training sizes are set as n = 250, 500 and 1000. Both examples are replicated 100 times. The averaged performance measures of our proposed method and Shiu and Gatsonis (2008) are reported in Table 1 . In addition, the ideal MCID's and their corresponding misclassification errors are used as baseline for the comparison in Table 1 . Table 1 about here In both examples, our proposed method yields accurate MCID estimates that are very close to the ideal MCID's. The resulting MCE's are also close to the MCE's produced by using the ideal MCID's. The performance of the method by Shiu and Gatsonis appears to be less competitive.
Even with a large sample size n = 1000, their estimated MCID's are still considerably different from the ideal MCID's.
Scenario II: personalized MCID
For personalized MCID, the MCE by using our proposed method with linear and Gaussian kernels are examined. The linear kernel is defined as K(z 1 , z 2 ) = z 
For each example, the training sizes are set as 100, 250, 500 and the testing size is set as 2000.
All examples are replicated 50 times, and the averaged test errors are reported in Table 2 . Table 2 here
Our proposed method delivers satisfactory performance in estimating the personalized MCID in all three examples. In addition, the linear kernel yields slightly better performance than the Gaussian kernel in Example 1 as the true classification boundary is linear, and it is outperformed by the Gaussian kernel in the other two examples with nonlinear boundaries. Therefore, the Gaussian kernel would be suggested if no prior knowledge about the boundary is available.
For estimating the personalized MCID, the choice of δ may impact the performance of our proposed method. By Theorem 2, large δ leads to less accurate prediction while computational instability may occur when small δ is used for the estimation. For illustration, we conducted a sensitivity analysis on the values of δ in a random replication of Example 1 with training size 250.
The estimated coefficients and prediction error as functions of δ are displayed in Figure 1 . It is evident that when δ is too large, the estimation of c(z) moves away from the truth and yields a larger error rate. When δ is close to 0, the error rate and estimation of c(z) are relatively stable.
Therefore, we recommend to set δ as 0.1 for simplicity. patients were used as the testing set.
Here, δ = 0.1 is used for simplicity and the tuning parameter λ is selected as in Section 5.2.
Each example is replicated 50 times, and Table 4 summarizes the averaged performance measures of the method by Shiu and Gatsonis, the population-based MCID, and the personalized MCID with the linear and Gaussian kernels. Table 3 
where E X represents the expectation with respect to X. It then suffices to find c * to maximize E(Y |X = x) sign(x − c) for any given x. Therefore, c * must satisfy that
for any x, where p(x) = P (Y = 1|X = x). We now show contradiction when p(c * ) = 1/2.
Without loss of generality, assume p(c * ) > 1/2. Since p(x) is continuous and monotone in x,
there must existc such that p(c) = 1/2 andc < c * . This leads to the contradiction to (16) since
Therefore, c * must satisfies p(c
. Furtheremore, when p(x) is continuous and strictly increasing, the uniqueness follows from the fact that p(c
has a unique solution.
Proof of Theorem 1. We first show thatĉ
By strong law of large number,
a.s.
−→ P (Y = −1). Further, it follows from
Theorem 19.1 of Van der Vaart (1998) that
uniformly over c. Therefore,
uniformly over c. Also by Lemma 1, ) ) has a unique minimizer c * when p(x) is continuous and strictly increasing in x. The desired asymptotic consistency follows immediately after Theorem 5.7 of Van der Vaart (1998).
Next, we establish the convergence rate of |ĉ − c * | by using Theorem 5.52 of Van der Vaart (1998). We just need to verify the necessary assumptions. Note that c * is the minimizer of
. Without loss of generality, for any c > c * , direct deviation yields that
where m c (x, y) = 1 2
(1 − y sign(x − c)).
Since f (x) is continuous at c * , it can be shown that P (c * ≤ X ≤ c * + ξ) ≥ a 9 ξ for sufficient small ξ > 0, where
by assumption (4)
which leads to a contradiction to the fact that ξ 1 < 1.
Since p(x) in continuous in x, there exists 0 < ξ 2 < ξ such that p(c
It can be shown similarly that
Therefore, there exists constant a 11 > 0 such that for sufficiently small ξ > 0,
Furthermore, denote F m = {m c (x, y) − m c * (x, y) : x ∈ R, y ∈ {−1, +1}}. Consider the grid
Note that
Then the functional brackets
forms L 1 (P ) brackets of size for F m with cardinality k < 2/ . Thus the bracketing
−2 ) and then the bracketing integral
for some constant a 12 < 0.
is an envelop function of m c − m c * with |c − c * | < ξ, and then assumptions (4) and (5) imply that
By Corollary 19.35 of Van der Vaart (1998),
Thereupon, denote A = 1 + 2/α 1 − α 1 γ 1 /2, it follows from Theorem 5.52 of Van der Vaart (1998) that for a sufficiently large integer M ,
Note that E δ−Y (X−c(z)) δ I(0 ≤ Y (X − c(z)) ≤ δ)|Z = z is decreasing in δ, and approaches 0
This implies that for any
The second term on the right hand side of (19) is bounded below by 0 and above by P |X−c| ≤ δ|Z = z and is decreasing in δ. Therefore, by Dini's theorem, P |X − c| ≤ δ|Z = z converges to 0 uniformly over
This, together with the fact that Step 1: First we introduce some notations.
Furthermore, by Assumptions A-C,
It immediately implies that
where P * denotes the outer probability measure.
Note that the functional space {c ∈ F : e(c, c * ) ≥ β 2 n } can be partitioned as For the first moment, note that for any c ∈ F,
Then with the assumption that λ max(
For the second moment, it follows from Assumptions B and C that for any c ∈ F, e(c, c
with a choice of ξ = (E| sign(X − c * (Z)) − sign(X − c(Z))|/4a 6 ) 1/α 2 . Now we are ready to establish an upper bound for the second moment. Note that for any d,
. Therefore, by the triangular inequality,
+ 1, and the last inequality is due to the fact that e(c, c
where i = 1, 2, · · · and j = 0, 1, 2, · · · . Now we are ready to establish the upper bound of I. Using (20) and (21), we have
Then we bound I 1 and I 2 separately by using 
for any > 0 and j = 0, 1, · · · , where These equalities do not hold in general. For instance, let p (x) = 0, when x ≥ c * and p (x) > 0 otherwise, then minimizers for all three losses are strictly larger than c * . 
